Medications for Acute Coronary Syndromes

alteplase, has an intermediate risk of intracranial hemorrhage and has a higher rate of recanalization than other fibrinolytics. Reteplase has the highest risk of intracranial hemorrhage and a recanalization rate similar to that of tenecteplase, and it is expensive. Streptokinase (not available in the United States) may induce allergic reactions, especially if it has been used previously, and must be given by infusion over 30 to 60 minutes; however, it has a low incidence of intracerebral hemorrhage and is relatively inexpensive. Anistreplase, related to streptokinase, is similarly allergenic and slightly more expensive but can be given as a single bolus. Neither drug requires concomitant heparin use. For both, recanalization rate is lower than that with other plasminogen activators. Because of the possibility of allergic reactions, patients who previously received streptokinase or anistreplase are not given that drug again. Alteplase is given in an accelerated or front-loaded dosage over 90 minutes. Alteplase with concomitant IV heparin improves patency, is nonallergenic, and has a higher recanalization rate than other fibrinolytics. TABLE IV Fibrinolytic Therapies Circulating half- Concurrent Allergic Medication life (minutes) heparin reactions Anistreplase 100 No Yes Alteplase 6 Yes Rare Reteplase 13â€“16 Yes Rare Streptokinase (not available in the 20 No
